AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.

Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).

LIBerate-HeFH_OLE is an open-label extension study investigating the use of lerodalcibep alongside oral lipid-lowering therapy in patients with CVD including HoFH who have successfully completed one of the phase 3 base studies. 703 patients were enrolled in the study and were followed-up after 48 and 72 weeks. The primary outcome measure was the incidence of treatment-emergent adverse events.

Interview Questions:

1.     What was the reasoning and the design behind the study?
2.    What are the take-home messages for practice? 
3.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers:  Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.